 Cellular Biomedicine Group, Inc. Nasdaq: CBMG CBMG or the Company, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the second quarter and six months ended June 30, 2020. 